 |
Clearing the Obstacles to Evidence-based ACS Care: New Strategies to Guide Practitioners CME Author Information and Disclosures Release Date: June 27, 2008; Valid for credit through June 27, 2009 | Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians | | This CME program is based on a satellite symposium that took place at an annual meeting, March 30, 2008, in Chicago, Illinois.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 INNOVIA Education Institute, LLC. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review new ACC/AHA/SCAI guidelines for STEMI, UA/NSTEMI, and PCI patients
- Examine gaps between evidence-based ACS treatment and practice in the United States and Europe and how the new guidelines will influence this gap
- Address challenges cardiologists face in adopting the new guidelines
- Increase guideline implementation in cardiology practice
Authors and Disclosures Elliott M. Antman, MD, Chair
Disclosure: Dr. Antman has disclosed he has received research support from Accumetrics, Amgen, AstraZeneca Pharmaceuticals, Bayer
Healthcare, Beckman Coulter, Biosite, Bristol-Myers Squibb Pharmaceutical Research Institute, CV Therapeutics, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck, Millennium Pharmaceuticals, National Institutes of Health (NIH), Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics Corporation, Roche Diagnostics GmbH, sanofi-aventis, Sanofi-Synthelabo Recherche, and Schering-Plough Research Institute. He
has served as a consultant or advisory board member for Momenta Pharmaceuticals and sanofi-aventis, as well as a lecturer for Eli Lilly and sanofi-aventis. Jeffrey L. Anderson, MD
Disclosure: Dr. Anderson has disclosed that he has received honoraria from Merck and sanofi-aventis and has served as a speaker for Merck. Eric R. Bates, MD
Disclosure: Dr. Bates
has disclosed that he has served on the advisory board of Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, The Medicines Company, and sanofi-aventis. He has received honoraria from Daiichi Sankyo, Eli Lilly, Hoffman-LaRoche, and sanofi-aventis, as well as research support from Daiichi Sankyo and Eli Lilly. Keith A. A. Fox, MB, ChB
Disclosure: Dr. Fox has disclosed that he has received grant support and honoraria from
GlaxoSmithKline, Merck Sharp & Dohme, and sanofi-aventis. Eric D. Peterson, MD, MPH
Disclosure: Dr. Peterson has disclosed that he has received research grants from BMS/sanofi, Schering-Plough, and Schering-Plough/Merck. Sidney C. Smith, Jr, MD
Disclosure: Dr. Smith has disclosed that he has received honoraria for speaking from Bayer, Pfizer, and
sanofi-aventis, and honoraria for consulting from Bristol-Myers Squibb, Eli Lilly, and sanofi-aventis. Ryan Nguyen, PharmD
Disclosure: Ryan Nguyen, PharmD, has disclosed that he has no relevant financial relationships. Content collaborators at INNOVIA Education Institute have disclosed that they have no relevant financial relationships. |
 |
Sponsored by INNOVIA Education Institute.
INNOVIA Education Institute designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
